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ABSTRACT
We have analysed the function of sequences in the
TATA/initiator region of the promoter of Ea, a class 11
gene of the Major Histocompatibility Complex. We find
that the Ea promoter contains an initiator element with
a strong influence on transcription. We also find that
the Ea promoter does contain a bona fide TATA box,
which can be recognized by the TATA binding protein
(TBP), and that TBP is required for transcriptional
activity. For activity, TBP must be included within a
larger TFIID complex, as Ea transcription in a heat-
treated extract can be restored by immunopurified
TFIID but not by TBP alone. On the other hand, the
TATA motif can be eliminated without significantly
affecting either the efficiency or the startsites of
transcription. This suggests that TBP, even in this
TATA-containing promoter, is held in place by other
components of the initiation complex, regardless of its
affinity for the underlying DNA.
INTRODUCTION
Class II genes of the Major Histocompatibility Complex (MHC)
encode heterodimeric membrane glycoproteins involved in a
number of key immunological processes. They form a family
of genes whose coordinated expression is elaborately regulated,
being confined to a set of cells involved in the selection and
activation of T cells (for reviews, see refs 1,2). The promoters
of these genes, either murine or human, have been studied in
detail by transgenesis, transfection into cultured cells and in vitro
transcription, leading to the definition of two upstream elements
of central importance-X and Y. The X box binds a number of
transcription factors; these X-binding factors seem to have binding
affinities and roles in transcriptional initiation which vary between
class II genes (for review and refs, see 2). The Y box of all class
II gene promoters, on the other hand, is recognized by the
heteromeric CCAAT binding factor NF-Y. It contains a
glutamine-rich activation domain, and is essential for the
transcription of all the MHC class II genes tested (3,4). The
promoter and enhancer activity of the X-Y motif is further
modified by additional regulatory elements found immediately
upstream of the X box in the S/W region, and by distant enhancer
elements.
How do these promoter motifs operate to position the RNA
polymerase in the preinitiation complex? To address this question
we decided to investigate the function of sequence elements
downstream of the X-Y motif, around the TATA box and the
cap site.
Among the different elements which make up eukaryotic
promoters for RNA polymerase II, the A/T-rich sequence known
as the TATA box was the first to be recognized and is the most
familiar (5). As the entry site for the general factor TFlID, which
nucleates the formation of the preinitiation complex in vitro, the
TATA box controls transcriptional initiation, both quantitatively
and by positioning the startsites (for review, see 6). The factor
thought to mediate the function of the TATA box, TFIID, is
actually a multi-subunit complex. It contains a DNA-binding
subunit, TBP, whose gene has recently been cloned from a
number of species (for refs, see 6). TBP is associated with a
number of other subunits, or TAFs (for TBP Associated Factors).
While TBP does not vary between cell types, the TAFs may be
heterogeneous in distinct forms of TFIID (7-11). The TFIID
complex is thought to be the target of transcriptional activators
or repressors (for review and discussion, see 6,12) and different
TAFs may be associated with stimulation by different classes of
activators (7-9). The central importance of TBP in eukaryotic
transcription was underscored by the discovery that it is also
essential for initiation by RNA polymerases I and mII (for review
and refs, see 13).
Given the pivotal role of the TATA box in the initiation of
transcription by polymerase II, it is paradoxical that a number
of genes do not contain recognizable TATA elements. These
include a number of housekeeping genes, transcribed at slow and
steady rates (reviewed in 14), but also tightly regulated genes
such as that for terminal-deoxynucleotidyl-transferase, whose
expression is strictly restricted to certain stages of lymphocyte
ontogeny and differentiation (e.g. 15 and refs therein). The
interpretation of these TATA-less promoters and of their mode
of operation is currently a matter of debate. Do they directly bind
TBP? Do they require TBP and TFIID at all? If so, how? (for
reviews, see 6,16).
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Most of the promoters of MHC class II genes do contain at
the expected position a TATA-like sequence that fits reasonably
well with the consensus: GATTTTAAT in Ea, TTATTAT in
Eb, TATTA in DRa, but the conservation in this region among
the different MHC Class II promoters is nowhere near that of
the xand Y motifs. We were prompted to study the role of TFIID
in the transcription ofMHC class II genes by an observation made
during a linker-scanning analysis of the Ea promoter: a drastic
10 bp mutation which eliminated the TATA box affected neither
the efficiency of transcription nor the position of the startsites
(17). Similarly, the TATA box in the Aa promoter did not seem
to play a strong quantitative role (18). These data suggested that
the TATA box in MHC class II genes is dispensible and does
not play its usual role in positioning initiation. It was even
conceivable, in theory, that TBP would not be involved in Ea
transcription.
To address these questions, we used recombinant TBP,
immunopurified TFIID and a TBP-specific affinity-purified
antibody. The data paint a somewhat unusual picture: the TATA
box of the Ea promoter can bind TBP, and TBP is indeed essential
for Ea transcription within a TFIID complex. Yet the affinity
of its binding to DNA is not a major determinant of promoter
efficacy. The TATA box does not appear to fix the transciptional
startsite, which rather results from the interplay between a strong
initiator element and the X-Y complex.
MATERIALS AND METHODS
Recombinant proteins
The recombinant rTBPh and rTFIIB proteins were expressed in
E.coli using the pET expression system based on the T7
promoter. The soluble proteins used in the footprinting assay were
purified essentially to homogeneity by ion exchange and DNA-
affinity chromotography, as described (19,20). The TFIIB-
expressing plasmid was a generous gift from D. Reinberg (21).
rTBPh used for immunizations and affinity-purifications was
prepared from inclusion bodies (80-90% pure TBP). These were
solubilized in 6M Guanidinium HCI. Five volumes of NDB
(1OOmM KCI, 20 mM Hepes ph 7.9, 0.5 mM EDTA, 1 mM
DTT, 20% glycerol) were added; the diluted material was kept
on ice for 10' and then extensively dialyzed against 500 ml of
NDB (6 hours, 2 buffer changes). To prepare columns for
affinity-purification of antibodies this renatured rTBPh (1 mg in
2 ml) was coupled to 800 1d of CNBr-activated Sepharose
(Pharmacia) according to the manufacturer's instructions.
Antibodies
A polyclonal mouse antiserum was raised by injecting mice with
purified human recombinant TBP in CFA. Specific anti-TBP
antibodies were purified from this serum as described (4).
The TBP column (see above) was washed with PBS and 1 ml
of mouse serum (diluted to 10 ml with PBS) was applied three
times; the column was then washed with 50 ml of PBS and the
bound antibodies eluted with 15 ml of 0. IM glycine pH2.8 (1
ml fractions neutralized with 500 ,tl of 1M Tris-HCI pH8.0).
Antibody-containing fractions were pooled, concentrated by
Centricon centrifugation and dialyzed extensively against PBS.
Antibody used in in vitro transcription experiments were further
dialyzed against NDB.
The anti-TBP monoclonal antibody 3G3 has been described
and was purified from ascites fluid as reported (7).
DNAase I footprinting
DNAse I footprinting consisted of a 30 min preincubation at 30°C
in a 20 IAI reaction volume containing 1 ng (10000 cpm) of
DNA probe, 100 ng of poly (dG-dC) (dG-dC), 0.05% NP-40,
5 mM MgCl2 and 50 mg/ml BSA in buffer A (50 mM
Tris-HCI pH 7.9, 0.1 mM EDTA, 0.5 mM DTT, 10%
glycerol, 50 mM KCI). rTBP (40 ng; > 95% pure) and rTF1IB
(20 ng; > 95% pure) were added as indicated. After the
preincubation, 2 I1 of DNAase I (10 mg/ml; Worthington, NJ)
was added for 2 min at 30°C and reactions were stopped by
adding 0.4 ml of a solution containing 0.5% SDS, 50mM sodium
acetate pH 5 and 50 mg/ml E. coli tRNA. DNA digestion products
were analyzed on 8% acrylamide-8 M urea gels.
Western blot and in vitro transcription
Western blot and in vitro reactions with nuclear extracts from
the murine B lymphoma CH27 and SI analysis were performed
exactly as detailed in refs 4 and 17. Heat inactivation of TFIID
was achieved by incubating the extract at 46°C for 15 minutes.
TFI) immunoprecipitation and purification
The phenyl 5PW fraction (here refered to as 4; see Figure 4)
was obtained as described (7). It was first dialysed against IP
buffer [Tris-HCI 25 mM pH7.9, 5 mM MgCI2, 10% glycerol,
0.1% NP40, 0.5 mM DTT, 0.1 M KCI]. To pre-clear the 4
fraction it was incubated with protein G-Sepharose (Pharmacia)
for 1.5 hours at 40C. The anti-TBP antibody/protein G complexes
were pelleted by centrifugation at 3000 rpm and then washed
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Figure 1. rTBP and rTFIIB bind the wild-type, but not the mutant, Ea TATA
box. DNAse I footprint was performed as described in materials and methods.
The DNA probes used encompassed the Ea promoter labelled on the non-coding
(A) or coding (B) strand. The fragment was either wild-type (left) or carried the
LS18 TATA box mutation (right). rTBPh and rTFIIB were added as indicated
at the top of each panel. In each case, the location of the TATA-box and initiation
site are indicated.
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5 times with IP buffer. The linked antibody/protein G-Sepharose
and the pre-cleared 4 fraction were then mixed and incubated
with rotation for 2 hours at 4°C. The complexes were
subsequently pelleted and washed 5 times with NDB buffer as
above. The first supernatant was conserved and tested in in vitro
transcription reactions. The immuno-precipitated TFIID
complexes were eluted by addition of an - 1000 fold excess
of peptide PA81 for 3 hours at 4°C with rotation [this peptide
is recognized by the binding site of the mAb 3G3 (22), and can
thus compete against antibody/TBP binding]. After centrifugation
at 3000 rpm the eluate was collected and tested by in vitro
transcription. Routinely 2-5 ml of fraction ) were precipitated
using 250 ,d of protein G-sepharose and 400 itg of the purified
antibody, and the TFIID was eluted in a 200-500 Al volume.
Gel retardation assays
1l1l of the CH27 nuclear extract used for in vitro transcription
was incubated with a double-stranded oligonucleotide (T-
CTTGTTAATTCTGCCTCAGTCTGCGATCG) corresponding
to sequences from positions -13 to + 17 of the Ea promoter,
in the following buffer: 50 mM NaCl, 10 mM Tris-HCl pH
7.5, 5% glycerol, 10 mM EDTA, 2 mM spermidine, 2 mM
DTT, 300 ng poly(dI-dC). After incubation for 20 minutes at
25°C, samples were loaded on a 5% acrylamide gel in 0.5 xTBE.
We also used initiatior region oligonucleotides from the promoter
of the Terminal-deoxynucleotidyl-transferase gene (TdT) (TCA-
GAGCCCTCATTCTGGAGACACCAC; position -11/+16;
ref 23) or the HIV promoter (TTGCCTGTACTGGGTCTCT-
CTGGTTAGACC; position - 12/+ 18; ref 24).
RESULTS AND DISCUSSION
TBP binds to the wild type but not a mutant Ea TATA box
Using 20 linker scanning mutants of the Ea promoter in
transfections and in vitro transcription studies, we have identified
the S, X and Y boxes as key regulatory elements (17). In this
set of experiments we created the mutant LS18, carrying a drastic
10 base mutation in the TATA box (between positions -35 to
-26; TTGGATTTTA to GGATCGATGC). Surprisingly, this
template yielded wild type levels of expression upon transfection
into MHC class fl-expressing B cells or macrophages, and only
a slight reduction of transcription in vitro (60% of wild-type
activity); in both cases, transcription was initiated at the correct
start site. Given the known loose DNA binding specificity of TBP
(25,26), we decided to verify whether the Ea TATA box was
indeed able to bind TBP and whether the mutant might stiTlretain
this in vitro binding capacity.
We used recombinant human TBP (rTBPh) purified as
described and recently shown to bind efficiently to the TATA
box of the Adenovirus major late promoter (AdML; 19). DNaseI
footprinting experiments were performed with fragments of the
wild type and LS18 mutant Ea promoters (positions -105 to
+60). As shown in Figure 1, a weak protection over the TATA
box appears on both strands when the wild-type DNA fragment
is preincubated with rTBPh alone (Fig. 1A, B lanes 1 and 2).
With the AdML template, the addition of recombinant TFI[B (21)
is known to stabilize the binding of TBP to the TATA box (20;
VM, unpublished). Here also, addition of rTFIIB, which by itself
does not bind (lanes 4), clearly enhances and modifies the
footprint (lanes 3), which then extends from positions -35 to
-5 relative to the Ea cap site; in addition, less prominent
hypersensitive sites appear around position -40. On both strands
the protection is centered on the TAAAATTA sequence. A region
of weak protection also appears, located further upstream in an
AT-rich stretch around position -60. In contrast, these footprints
are essentially absent after parallel incubations of TBP and/or
TFIIB with an Ea promoter fragment carrying the LS18 mutation
in the TATA box (Figure LA, B).
These results indicate that the Ea TATA box binds TBP and
that this interaction is stabilized by the presence of TFIIB. These
features are essentially lost in the LS18 TATA-box mutant,
confirming that the mutation does prevent TBP binding in vitro,
at least at the level of sensitivity provided by footprinting assays.
TBP is necessary for Ea transcription with wild type and LS
18 templates
Because of the normal transcriptional activity of the TATA mutant
in spite of the apparent absence of TBP binding, we felt it
important to investigate whether TBP was indeed required for
Ea transcription. This was ascertained by transcription in vitro,
with two lines of experimentation: we attempted to inhibit Ea
transcription with affmnity-purified antibodies to TBP; we also
tested whether Ea transcription was heat-sensitive, a well-known
characteristic of TBP and TFIID (27).
We used the in vitro transcription system consisting of the Ea
promoter (-215 to + 12) fused to a ,B-globin reporter gene (in
the plasmid PE3; ref. 17) incubated with nuclear extracts from
MHC class II+ B cells of the CH27 lymphoma line; accurately
initiated RNA was quantitated by Si-nuclease mapping. This
transcription system has been shown to faithfully reproduce the
in vivo situation, in that the start sites are accurate and
transcription is fully dependent on the xand Y motifs (17,28).
Anti NF-Y antibodies also have a profound inhibitory effect (4).
We are thus dealing with an in vitro system that is dependent
on upstream activators.
Antibodies against TBP were raised in mice immunized with
recombinant TBP and purified over an affinity column containing
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Figure 2. Anti-TBP antibodies inhibit Ea transcription in vitro. A: Western blot
analysis ofCH27 nuclear extract (200 dig) with affinity purified anti-TBP antibodies.
The band corresponding to TBP has the expected molecular weight (38KD).
B: Ea WT and Ea LS18 TATA-mutant template DNA were used for in vitro
transcription assays using anti-TBP (lanes 1,2,5,6) or control antibodies (affinity
purified rabbit anti-HEL; lanes 3,4,7,8). The antibodies (1 jg) were incubated
with the extract for 15' on ice, before addition of template DNA and nucleotides.
In lanes 2, 4, 6 and 8 the inhibitory effect of the antibodies was blocked by
preincubation with rTBPh (100 ng).
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Figure 3. rTBPh restores SV40E and AdML, but not Ea transcription in a heat-
treated CH27 nuclear extract. Normal or heat- ted (15' at 460C) CH27 nuclear
extracts were used for in vitro transcription driven by Ea and SV40E Oanes 1-4)
or AdML (lanes 5-8) promoters. The intemal control (SVCtl in lanes 1-4)
consists of the SV40 enhancer and early promoter; the AdMLP contains just the
TATA and Inr elements. All promoters are placed in front of a rabbit ,B-globin
reporter gene (see ref 4); transcription was evaluated by SI mapping, as above.
TBP linked to a Sepharose solid support, an essential step to
obtain high affinity antibodies of narrow specificity. This
approach also ensured that our preparation contained antibodies
directed to different epitopes of TBP. The specificity of our
purified anti-TBP preparation was verified by Western blotting
with transcription-competent nuclear extracts: a single major band
was detected, at the expected position for the 38 Kd TBP protein
(Figure 2A).
Preincubation of the nuclear extract with the purified antibody,
before the addition of template DNA and nucleotides, abolished
transcription from the normal Ea start site at position +1
(Fig. 2B, lane 1). Control antibodies (affinity purified rabbit anti-
lysozyme, see 4) had no effect on transcription (lane 3). As
evidence for the specificity of the antibody inhibition, the effect
could be blocked by preincubating the antibody with recombinant
TBP prior to addition of extract, resulting in complete restoration
of transcription (lane 2). Interestingly, and also confirming the
specificity of the inhibition, the antibodies had no negative effect
when added a few minutes after preincubation of the nuclear
extract with template DNA (data not shown). This behaviour,
which parallels observations with anti-NF-Y antibodies (4),
indicates that the antibodies cannot affect a formed pre-initiation
complex.
In parallel experiments we tested the effect of the anti-TBP
antibody on transcription driven by the LS18 mutant promoter:
the pattern observed was identical to that obtained with the wild
type promoter (Fig. 2B, lanes 5-8; the heavy band on top of
the lanes corresponds to TBP-independent read-through
transcription, compressed at the position of the mutation by Si
cleavage). The anti-TBP antibody was also effective in inhibiting
AdML promoter-driven tanscription with CH27 nuclear or Hela
whole cell extracts (RM, VM, data not shown).
These data demonstrate the TBP-dependance of both the wild
type and TATA-mutant Ea promoters, ruling out the possibility
that, because of the difference in TBP binding, they might act
through different mechanisms.
To confirm these data, and to test how TBP might function
in initiation of Ea trancription, we tested the efficiency of Ea
driven templates in heat-treated nuclear extracts. TBP, and more
generally TFIID, is quicldy inactivated by incubation of extracts
at moderate temperatures; several groups have shown that this
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Figure 4. Purification of TBP-asociated factor(s) necessary for Ea transcription.
A: The general purification scheme, following TFIID activity through several
chromatographic steps (for details see ref 7). B: an SDS-PAGE analysis of faction
4, after inmmunoprecipitation with an anti-TBP monoclonal antibody and elution
with the specific peptide. The band coesding to TBP was idenified by Western
blotting (not shown). Some contamination is apparent from the immunoglobulin
used for immunoprcipitation (IgGH and L). Panel C shows the ability of various
fractions to functionally complement a heat-treated CH27 extract for Ea
transcription in vitro. Lane 2: no addition: lane 3: fraction gb (see A); lane 4:
the supernatant remaining after immunoprecipitation from fraction 4 with anti
TBP antibody; lane 5: TFIID released from anti-TBP immunoprecipitates by
addition of an excess of peptide (see Methods). The globin ctl consists of the
rabbit gl-globin promoter (7) driving the same 0-globin reporter segment as the
Ea promoter. Transcription was evaluated by Sl-mapping.
loss of activity can be restored, for TATA-containing promoters,
by the addition of recombinant TBP (for review and refs, see 6).
A 15 minute treatment of the CH27 nuclear extract at 46°C
did indeed inactivate transcription from the Ea promoter, from
the SV40 early promoter used here as an internal control, and
from a minimal promoter containing just the AdML TATA box
and initiator (Figure 3, lanes 3,7). Addition of recombinant TBP
brought back substantial amounts of the SV40E and AdML
transcripts, but not of the Ea transcripts initiated at position + 1
(lanes 4,8). The lack of restoration of Ea transcription is not a
simple quantitative effect, since high doses of rTBPh were used
here (100ng per transcription reaction), and no effect was seen
at even higher doses. On the other hand, an activity restoring
Ea transcription in heat-teated extacts could be found to copurify
with TEIID through several purification steps from crude nuclear
extracts [Heparin-Ultrogel and Phosphocellulose (PC) columns;
data not shown, Figure 4A]. We then used the TFIID
immunopurification protocol recently established by some of us
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Figure 5. An initiator element is important for Ea promoter function. A. The
CH27 in vitro transcription system was used with the WT plasmid PE3 and with
the mutants PE-LS21, PE-I.2 and PE-I.3, whose sequences are shown in C.
Transcription was evaluated by quantitative SI mapping, as above. B. CH27
proteins binding to Ea initiator oligo are compared in electrophoretic mobility
and cross-competition experiments with TdT and HIV initiator-binding factors.
C. Mutations introduced in the PE mutant plasmids are shown together with the
WT Ea sequence.
(7). In this protocol, TBP and its associated TAFs are
immunoprecipitated with a monoclonal antibody (3G3), and can
subsequently be released by an excess of a peptide which carries
the antibody's epitope, namely the N-terminal 17 amino acids
of TBP. As shown in Figure 4B, the fraction obtained by peptide
elution after immunoprecipitation contains a discrete set of
proteins as well as TBP (which can be identified by Western
blotting; not shown).
Figure 4C presents the functional results of this fractionation
scheme. To a limited degree, Ea transcription in the heat-treated
CH27 extract can be restored by a partially purified fraction which
contains TFIID (o in Figure 4). The complementing activity is
depleted in the supernatant remaining in this fraction after
immunoprecipitation with the anti-TBPmAb (lane 4). In contrast,
the peptide eluate obtained from the pellet after
immunoprecipitating this fraction with the anti-TBP mAb is
considerably enriched in complementing activity (lane 5).
Interestingly, complementation is very much stronger than with
the starting fraction, suggesting that an inhibitor might copurify
with TFIID, but be removed by the immunoprecipitation
procedure. The complementing activity in the immunoprecipitated
pellet is, itself, heat-sensitive, being largely inactivated at 46°C
(not shown). Here again, the LS18 mutant behaves like the wild-
type promoter, and the same TAF-containing eluted TFIID
fraction also restores its activity in a heat-treated extract (not
shown).
Together with our previous results (17), the present data show
a somewhat unusual behaviour of the Ea promoter.
On the one hand, it does contain a bona fide TATA box: the
-32 to -24 motif fits the degenerate TATA consensus, and it
binds TBP in what appears to be a relevant manner, since the
binding is stabilized by TFIIB, as happens on a classical TATA-
containing promoter such as AdML (Figure 1 and data not
shown). TBP is also necessary for Ea transcription, which is
specifically and completely inhibited by the anti-TBP antibody
(Figure 2).
On the other hand, this TATA box is expendable for
transcription in quantitative and qualitative terms, suggesting that
Ea operates like a TATA-less promoter: the LS18 mutation does
abolish the TBP binding detectable in the footprinting assay
(Figure 1), but affects neither the efficiency of transcription nor
the position of the startsite (17, and Figure 2). The LS18 mutant
also behaves like the wild-type promoter, requiring for function
TBP within a heat-sensitive TFIID complex which cannot be
replaced by TBP alone (Figures 2, 3 and 4).
At this point, one cannot overlook the parallel between our
data and those of Pugh and Tjian (31), using an artificial TATA-
less promoter: in both cases, TBP binding to DNA, assayed by
footprinting, is absent or unimportant, yet TBP itself is critical;
transcription is dependent on a dominant upstream activator
together with an initiator; this activator contains glutamine-rich
activation domains; and transcription requires a thermolabile
TFIID complex, other than TBP, which is not as essential for
TATA-containing promoters. Pugh and Tjian (31) have proposed
that TBP does not bind DNA in TATA-less promoters, but is
held in place by a 'tethering factor'. Based on this analogy, one
would propose that, for the Ea promoter, the primary force which
holds TBP in place is not its affinity for the Ea TATA box, but
rather protein/protein interactions with other factors. Here also,
the requirement for a TAF to anchor TBP might account for the
fact that isolated TBP is strictly incapable of restoring Ea
transcription in a heat-treated extract. Whether this TAF is itself
heat-sensitive, or simply cannot exchange from an inactivated
TFIID complex onto fresh TBP, remains an open question, as
in Pugh and Tjian's experiments.
Our results are compatible with the mutagenesis study of
Dedrick and Jones (18), but appear somewhat at odds with those
of Matsushima et al. (32), which implied an important role of
the TATA box for transcription of DRa, the human homolog
of Ea. In that study, though, an estimation of the amounts of
correctly initiated RNAs was hampered by the low resolution
and the apparent high variability of the in vitro analysis.
Otherwise, it is quite possible that the balance of initiation factors
is different in DRa compared to other MHC class II genes, due
to the presence of an octamer binding site between the Y box
and the TATA box, a site which appears unique to DRa.
The Ea promoter contains a strong initiator motif
If the TATA box is dispensible for the selection of transcriptional
startsites, how is initiation positioned? Initiator motifs located
immediately at the cap site are known to perform this positioning
function in several TATA-less promoters (e.g. 23,29,30). The
existence of an initiator element in the Ea promoter was made
all the more plausible by the existence of sequence similarity
between sequences at the Ea capsite and the TdT initiator motif
(GCCTCAGTCTGC and CCCTCATTCTGG). We thus
introduced several mutations in this region of our PE3 plasmid
(sequences shown in Figure 5C), and tested these mutant
templates in the in vitro transcription assay (Figure 5A). The ten
base replacement in the PE-LS21 mutant led to a severe drop
in Ea transcription (to 5% i 2 of WT transcriptional efficiency
in four independent experiments), while the PE-I.2 and PE-I.3
were crippled to a lesser, but still significant degree (to 33% 4
and 30%' 5, respectively). Note that in all the mutants only
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the correct Ea + 1 signal was influenced, whereas the spurious
-25 transcript remained largely unchanged.
To further substantiate the existence of an initiator element in
Ea, we compared the factor-binding potential of this region with
that of other known initiator motifs. A ds-oligonucleotide covering
the Ea initiator region was used in parallel and in cross-
competition with oligonucleotides of similar sizes containing
know initiator motifs from the TdT and HIV promoters (23,24).
As shown in Figure SB, the binding pattern observed with the
Ea oligo is complex: four diferent bands are observed; they
appear specific in that all are eliminated by competition with an
excess of cold WT Ea oligo, but not by an oligo containing the
drastic LS21 mutation.
Interestingly, one of the bands (band 4) roughly comigrates
with a retarded band observed with the TdT oligo. That the Ea
and TdT motifs bind the same factor is further substantiated by
the efficient cross-competition for binding at this position. In
contrast, the other retarded bands observed with the Ea oligo
are not competed off by the TdT oligo.
One of these, band 2, appears shared between the Ea and HIV
templates. Band 2 seen with the Ea template comigrates with the
major retarded band found with the HIV template, and there is
efficient cross-competition between the templates. This band
might correspond to the LBP1 factor described by Kato et al (24),
as it is abolished by mutations in the HIV oligo which inhibit
LBP1 binding (data not shown). Note that band 2 is unrelated
to band 4 (and the major band seen with the TdT oligo), as there
is no cross-ompetition between TdT and HIV oligos.
In summary, the Ea promoter contains a strong initiator element
of profound functional importance. It binds a complex set of
proteins, related in part to several independent factors which bind
initiator motifs in other genes. This complexity will need to be
unravelled in further studies.
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CONCLUSIONS
What, then, does the choice of the initiation sites in Ea actually
depend on? Previous analyses with transgenic mice strongly
implicated the upstream X and Y boxes (33; Viville et al.,
unpublished). Our present data also point to the influence of an
initiator element at the cap site. One is left with the notion that
the position of the initiation site in Ea depends on the conjunction
of the strong promoter/enhancer elements at the X-Y motif with
the initiator element which serves to focus transcription.
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